Business Context and Reporting Period
Oramed Pharmaceuticals Inc. filed this Form 8-K on June 13, 2016, reporting the entry into a Material Definitive Agreement. The Company's wholly-owned subsidiary, Oramed Ltd., entered into a Service Agreement with XERTECS GmbH to support manufacturing operations in China.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the specific agreement terms:
- Total Consideration: Up to €2,360,000.
- Upfront Fee: €800,000 (non-refundable, payable within 12 months).
- Remaining Fee: Payable over the term based on milestone achievement.
Material Changes
The filing discloses a new contractual obligation rather than a change in historical financial performance. The agreement is a requirement under the Amended and Restated Technology License Agreement with Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT), previously disclosed in December 2015.
Outlook, Risks, and Management Commentary
Agreement Purpose: XERTECS will provide services to HTIT to enable the manufacturing of the product ORMD-0801 in the People's Republic of China, Macau, and Hong Kong at HTIT's facilities.
Term: Four years from the Effective Date (June 13, 2016).
Risks/Contingencies: A portion of the payment is contingent upon the achievement of certain milestones. The filing does not explicitly list other risks or contingencies beyond the standard nature of milestone-based payments.
Key Facts for Investor Verification
- Verify the status of the underlying Technology License Agreement with HTIT dated December 21, 2015.
- Confirm the specific milestones required to trigger the remaining payments beyond the €800,000 upfront fee.
- Assess the progress of ORMD-0801 manufacturing capabilities at HTIT's facilities in China.
- Review the Company's cash position to ensure it can fund the €800,000 non-refundable fee within the next 12 months.